AI predicts better kidney care

AI models offer an early look into who might develop kidney disease, who would benefit from early intervention, and the risk of further complications without a change in course. However, it is worth taking a close look to ensure any bias or gaps are addressed.  

M&A: Centene to Acquire AI Healthcare Analytics Platform Apixio

M&A: Centene to Acquire AI Healthcare Analytics Platform Apixio

What You Should Know:

– Centene Corporation acquires AI healthcare analytics platform
Apixio to additional data and AI capability to technology portfolio.

– Apixio will remain an operationally independent entity
as part of Centene’s Health Care Enterprises group to continue bringing value
to its clients and the industry.

Centene Corporation, today
announced it has signed a definitive agreement to acquire
Apixio Inc., a AI healthcare analytics company offering Artificial
Intelligence (AI)
technology solutions. The transaction is subject to
regulatory approvals and is expected to close by the end of 2020.

Better Data. Better Healthcare

More than 1.2 billion clinical documents are generated each year in the U.S., but there is very little analysis of that unstructured information. Founded in 2009. Apixio helps organizations use their data for knowledge about patient health. This ultimately translates into more effective care delivery, lower costs and streamlined processes. Apixio’s machine learning and deep learning algorithms analyze unstructured data embedded in electronic health records, scanned notes, facsimiles, and handwritten notes to produce high-quality predictions for measurement, care, and discovery.

The Apixio Platform

M&A: Centene to Acquire AI Healthcare Analytics Platform Apixio

The Apixio Platform can mine textual data and combine its generated insights with available structured data to craft computable individual health profiles or phenotypes. We analyze our assembled phenotypes in real-time using a flexible rules engine. This automates the execution of clinical guidelines, quality and risk measures, payment or reimbursement policies, and other operational and administrative rules, to support critical healthcare activities.

Acquisition Complements Centene’s Existing Data Analytics
Products

“Centene is committed to accelerating innovation, modernization and digitization across the enterprise and solidify its position as a technology company focused on healthcare. Apixio’s capabilities are closely aligned with our plans to digitize the administration of healthcare and to leverage comprehensive data to help improve the lives of our members,” said Michael F. Neidorff, Chairman, President and Chief Executive Officer for Centene. “Apixio’s technology will complement existing data analytics products including Interpreta, creating a differentiated platform to broaden support for value-based healthcare payment and delivery with actionable intelligence.”

As part of the acquisition, Apixio will remain an
operationally independent entity as part of Centene’s Health Care Enterprises
group to continue bringing value to its clients and the industry, while also
realizing the benefits of enhanced scale with Centene. Financial details of the
acquisition were not disclosed.

Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China

Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China
Front row (left to right): Jian Chen, Vice President, Xian Janssen Pharmaceuticals; Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific; Sharona Tao, Leader, Communications & Public Affairs, Johnson & Johnson China; Jennifer Yang, Head, Lung Cancer Initiative China, Johnson & Johnson Back row (left to right): Alex Zhavoronkov, Founder & CEO, Insilico Medicine; Li Peng, Assistant General Manager, Taikang Online Insurance; Gary Ge, Founder, Diannei

What You Should Know:

– Johnson & Johnson Innovation announces three strategic
collaborations with a focus on advancing healthcare solutions in China.

– The three strategic collaborations are focused on leveraging advances in science and technology to address areas of high unmet medical need across several areas, including discovery science, lung cancer, and medical devices


Johnson & Johnson Innovation, a division of Johnson & Johnson (China) Investment Limited, today announced three new collaborations with strategic partners in China. These latest collaborations, facilitated by the Johnson & Johnson Asia Pacific Innovation Center, showcase its broad innovation efforts and focus on leveraging advances in science and technology to address areas of high unmet medical need across several areas, including discovery science, lung cancer, and medical devices.

The collaborations are as follows:

1. Leveraging AI in drug discovery – Janssen Pharmaceutica NV, one of the
Janssen Pharmaceutical Companies of Johnson & Johnson, has established a
multi-target drug discovery collaboration with Insilico Medicine Hong Kong
Ltd., a Johnson & Johnson Innovation – JLABS @ Shanghai resident
company specializing in AI-based drug
discovery.

The agreement will leverage Insilico Medicine’s AI-based platform to design small-molecule hits with the defined properties for several targets nominated by Janssen. The collaboration aims to generate novel and fully patentable chemical scaffolds for difficult targets using AI-based drug designing, potentially leading to significant reductions in time and cost in identifying biologically active hits against selected targets.

2. Developing AI solutions for lung cancer detection
– The Lung Cancer Initiative at Johnson & Johnson in China,
through its affiliate Johnson & Johnson (China) Investment Limited, has entered
into a research collaboration with Diannei (Shanghai) Biotechnology Co. Ltd., a
Chinese company specializing in AI solutions for lung cancer management. The
agreement will see both parties work together to develop computer vision AI for
lung cancer diagnosis. Diannei’s expertise is in developing AI solutions with
deep learning for medical image analysis.

3. Innovative healthcare solutions for sports injury
– Johnson & Johnson Medical (Shanghai) Limited (JJMS) announced an
agreement with Taikang Online Insurance Co. Ltd. (Tk.cn), a Chinese online
healthcare insurance company, to develop an innovative sports injury-related
insurance package. JJMS will support Tk.cn by offering its industrial insights,
while Tk.cn designs reimbursement coverage to sports enthusiasts which aim to
enable timely diagnosis and appropriate surgical treatment for patients.

Why It Matters

“Johnson & Johnson has deep roots in China for the past 35 years to address the growing needs of patients and consumers. We are delighted to mark the third annual CIIE, a significant platform that supports the expansion, innovation and internationalization of the Chinese business environment, by announcing these new collaboration agreements,” said Will Song, Global Senior Vice President, China Chairman, Johnson & Johnson*. “These agreements span a diverse range of focus areas and represent a valuable opportunity to advance human health for the country by connecting global and local innovators with the expertise of the Johnson & Johnson Family of Companies to help transform great ideas into breakthrough solutions.”

Innovaccer Launches AI-Enabled Patient Relationship Management Solution

Innovaccer Launches AI-Enabled Patient Relationship Management Solution

What You Should Know:

– Innovaccer launches its artificial
intelligence (AI)-enabled patient relationship management solution to
streamline communication between patients and their care teams.

– The solution enables
providers and member teams to move beyond treating illness to facilitating
proactive care by building productive, long-term relationships with patients.


Innovaccer, Inc., a San Francisco, CA-based healthcare technology
company, today launched its artificial
intelligence (AI)-
enabled patient relationship management solution to streamline communication between patients and their care
teams. The solution increases revenue by helping care staff use their time more
efficiently, enabling personalized outreach over a broad patient base with
comprehensive, data-driven, and fully-coordinated care.

The absence
of widely available, easy-to-use systems that automate tasks, such as
scheduling follow-up calls, developing and distributing targeted
communications, and properly responding to questions, makes managing ongoing
relationships difficult, especially for patients with complex medical
conditions. To eliminate such communication barriers, the solution uses
powerful analytics to provide a 360-degree view of patients along with their
utilization trends to easily stratify the most vulnerable patients. With these
views in place, providers can take suitable steps and group patients based on
shared conditions or goals for improved medical management and care delivery.

Enabling
2-Way Communication at Population & Individual Levels

Built on top of Innovaccer’s proprietary FHIR-enabled Data Activation Platform, the solution enables HIPAA-compliant, two-way communication channels to engage patients at both the population and individual levels. The solution enables care teams to easily manage appointments, monitor patient ratings, and feedback, and conduct one-click appointment booking and prescription renewals. With the solution, the care teams can create patient cohorts based on disease, region, and various other parameters to send bulk outreach emails. It simplifies the process of connecting healthcare teams with patients to provide administrative and clinical support.

“Patient-centricity is the essence of healthcare, and artificial intelligence has always been viewed as the answer to achieving individualized, consumer-oriented healthcare,” says Abhinav Shashank, CEO at Innovaccer. “With our patient relationship management solution, we will   resolve the complexity that prevents healthcare organizations from building strong patient relationships. Our goal is to enable healthcare teams to care as one for their patients.”